Natco Pharma Ltd - Legal Update on launch of CTPR

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced that FMC Corporation and FMC Singapore have served a copy of appeal on Natco. The Appeal is against the well-reasoned and clear judgement of the Hon'ble High Court of Delhi dated 19th September, 2022 which enabled Natco to launch its CTPR (Chlorantraniliprole) products.

Natco is confident of its case and is confident of its success in the appeal.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 585.75 as compared to the previous close of Rs. 589.55. The total number of shares traded during the day was 6889 in over 793 trades.

The stock hit an intraday high of Rs. 594.95 and intraday low of 582.75. The net turnover during the day was Rs. 4056389.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 LegalUpdate